Barclays raises Celestica price target to $414 from $406
Barclays maintained its Overweight rating on Celestica while raising its price target from $406 to $414 per share.
Related stories
Reservoir Link Energy Insiders Acquire MYR 626,944.50 in Shares
Reservoir Link Energy insiders acquired shares worth MYR 626,944.50.
M impact | EQUITY | Oct 29, 2026, 09:17 AM UTC
Ambuja Cements Q2 Net Profit Falls 89.9% to ₹236 Crore
Ambuja Cements reported September-quarter net profit of ₹236 crore, down from ₹2,336 crore a year earlier and below the CNBC-TV18 estimate.
M impact | EQUITY | Oct 29, 2026, 09:16 AM UTC
Shadowfax Q2 Profit Rises to ₹68 Crore as Revenue Grows 57%
Shadowfax Technologies reported net profit of ₹68 crore for the September quarter, up from ₹13 crore a year earlier. Revenue grew 57% year on year.
M impact | EQUITY | Oct 29, 2026, 09:16 AM UTC
Beijing Capital Development Reports Q3 Net Loss of 1.1 Billion Yuan
M impact | EQUITY | Oct 29, 2026, 09:16 AM UTC
Apar Industries Shares Gain 5% After Q2 Profit and EBITDA Beat Estimates
Apar Industries reported second-quarter profit after tax of ₹447 crore, versus a CNBC-TV18 poll estimate of ₹339 crore and ₹51.7 crore a year earlier. Shares gained 5%, and margins
M impact | EQUITY | Oct 29, 2026, 09:16 AM UTC
Senores Pharmaceuticals Shares Fall 3% as Q2 Profit Rises 22%, Revenue 25%
Senores Pharmaceuticals shares fell 3% despite increases in quarterly profit and revenue. The body says results were for the quarter ended in September 2026.
M impact | EQUITY | Oct 29, 2026, 09:16 AM UTC